These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20971669)

  • 1. Short-term effect of IL-6 inhibition in spondylarthritis.
    Wendling D; Bossert M; Prati C
    Joint Bone Spine; 2010 Dec; 77(6):624-5. PubMed ID: 20971669
    [No Abstract]   [Full Text] [Related]  

  • 2. Mixed effect of tocilizumab in spondylarthritis. Comments about the article by Wendling et al. entitled "Short-term effect of IL-6 inhibition in spondylarthritis". Joint Bone Spine 2010;77:624-5.
    Malochet-Guinamand S; Soubrier M
    Joint Bone Spine; 2012 Jan; 79(1):106; author reply 106-7. PubMed ID: 22041094
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al.
    Wendling D
    Arthritis Care Res (Hoboken); 2010 May; 62(5):745; author reply 745-6. PubMed ID: 20191469
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful adalimumab treatment of HLA B27 negative heel enthesitis documented with MRI and US.
    Mancarella L; Battaglia M; Addimanda O; Pelotti P; Galletti S; Meliconi R
    Clin Exp Rheumatol; 2010; 28(3):443-4. PubMed ID: 20576232
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term changes in magnetic resonance imaging and disease activity in response to infliximab.
    Bonel HM; Boller C; Saar B; Tanner S; Srivastav S; Villiger PM
    Ann Rheum Dis; 2010 Jan; 69(1):120-5. PubMed ID: 19329424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
    Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L
    Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis.
    Olivieri I; D'Angelo S; Palazzi C; Leccese P; Nigro A; Padula A
    Reumatismo; 2013 Mar; 65(1):1-3. PubMed ID: 23550255
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index.
    Maksymowych WP; Mallon C; Morrow S; Shojania K; Olszynski WP; Wong RL; Sampalis J; Conner-Spady B
    Ann Rheum Dis; 2009 Jun; 68(6):948-53. PubMed ID: 18524792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New synthetic and biologic treatments for spondylarthritis].
    Zufferey P
    Rev Med Suisse; 2016 Mar; 12(509):512, 514-6. PubMed ID: 27089641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seronegative spondyloarthritis and magnetic resonance imaging.
    Maksymowych WP
    J Rheumatol; 2009 Jan; 36(1):200-1; author reply 201. PubMed ID: 19208535
    [No Abstract]   [Full Text] [Related]  

  • 11. Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?
    Maksymowych WP
    Nat Rev Rheumatol; 2013 Sep; 9(9):507-8. PubMed ID: 23917954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New evidence on the management of spondyloarthritis.
    Sieper J; Poddubnyy D
    Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.
    Mok CC; Li OC; Chan KL; Ho LY; Hui PK
    Scand J Rheumatol; 2015; 44(6):480-6. PubMed ID: 26271141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed response to tocilizumab for ankylosing spondylitis.
    Henes JC; Horger M; Guenaydin I; Kanz L; Koetter I
    Ann Rheum Dis; 2010 Dec; 69(12):2217-8. PubMed ID: 20525837
    [No Abstract]   [Full Text] [Related]  

  • 15. The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
    Troppmann L; Karsh J;
    J Rheumatol; 2008 Apr; 35(4):658-61. PubMed ID: 18278833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
    Pedersen SJ; Sørensen IJ; Lambert RG; Hermann KG; Garnero P; Johansen JS; Madsen OR; Hansen A; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen KH; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Østergaard M
    Arthritis Rheum; 2011 Dec; 63(12):3789-800. PubMed ID: 22127697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply: To PMID 25545240.
    Mease P; Sieper J; Van den Bosch F; Rahman P; Pangan A
    Arthritis Rheumatol; 2015 Oct; 67(10):2793-4. PubMed ID: 26097157
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply: To PMID 25545846.
    Gladman DD
    Arthritis Rheumatol; 2015 Nov; 67(11):3096. PubMed ID: 26245189
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: What is peripheral spondyloarthritis?
    Gladman DD
    Arthritis Rheumatol; 2015 Apr; 67(4):865-8. PubMed ID: 25545846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.